Polivy (polatuzumab vedotin)

pCPA File Number: 22584

Negotiation Status:

Active Negotiation

Indication(s):

Large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL, previously untreated in adult patients. (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP))

Sponsor/Manufacturer:

Hoffmann-La Roche Ltd.

CDA-AMC Project Number:

PC0313-000

pCPA Engagement Letter Issued:

2024-07-26

Negotiation Process Concluded:

Not Applicable